AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] SeaStar Medical Holding Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Centene Corporation (CNC) â€� Form 4 insider filing

Director Kenneth A. Burdick reported a modest open-market acquisition of 556 Centene common shares on 30 June 2025 (transaction code A). The shares were acquired at a stated price of $0.00, suggesting the issuance relates to compensation or dividend reinvestment rather than a cash purchase. Following the transaction, Burdick’s direct ownership increases to 367,052.924 shares. He also reports 86,498 indirect shares held through Burdick Family LLC, bringing his aggregated economic interest to roughly 453.6 thousand shares.

The filing also discloses an existing stock option for 10,000 shares with a strike price of $80.57, exercisable from 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transactions were recorded.

While insider purchases are generally viewed as a confidence signal, the 556-share addition represents less than 0.2 % of Burdick’s current stake and is immaterial to Centene’s overall float. The transaction therefore carries limited fundamental impact but modestly reinforces management–shareholder alignment.

Centene Corporation (CNC) � Comunicazione interna Form 4

Il direttore Kenneth A. Burdick ha segnalato un modesto acquisto sul mercato aperto di 556 azioni ordinarie Centene in data 30 giugno 2025 (codice transazione A). Le azioni sono state acquisite a un prezzo dichiarato di $0,00, suggerendo che l’operazione riguarda una compensazione o un reinvestimento di dividendi piuttosto che un acquisto in contanti. Dopo la transazione, la proprietà diretta di Burdick sale a 367.052,924 azioni. Riporta inoltre 86.498 azioni indirette detenute tramite Burdick Family LLC, portando il suo interesse economico aggregato a circa 453,6 mila azioni.

La comunicazione evidenzia anche un’opzione su azioni esistente per 10.000 azioni con un prezzo di esercizio di $80,57, esercitabile dal 7 febbraio 2025 e in scadenza il 7 febbraio 2032. Non sono state registrate nuove transazioni su strumenti derivati.

Pur essendo generalmente interpretati come un segnale di fiducia, i 556 azioni acquistate rappresentano meno dello 0,2% della partecipazione attuale di Burdick e sono irrilevanti rispetto al flottante complessivo di Centene. Pertanto, la transazione ha un impatto fondamentale limitato ma rafforza modestamente l’allineamento tra management e azionisti.

Centene Corporation (CNC) � Presentación interna Formulario 4

El director Kenneth A. Burdick reportó una modesta adquisición en el mercado abierto de 556 acciones ordinarias de Centene el 30 de junio de 2025 (código de transacción A). Las acciones fueron adquiridas a un precio declarado de $0.00, lo que sugiere que la emisión está relacionada con compensación o reinversión de dividendos en lugar de una compra en efectivo. Tras la transacción, la propiedad directa de Burdick aumenta a 367,052.924 acciones. También reporta 86,498 acciones indirectas mantenidas a través de Burdick Family LLC, sumando un interés económico agregado de aproximadamente 453.6 mil acciones.

La presentación también revela una opción sobre acciones existente para 10,000 acciones con un precio de ejercicio de $80.57, ejercitable desde el 7 de febrero de 2025 y con vencimiento el 7 de febrero de 2032. No se registraron nuevas transacciones de derivados.

Si bien las compras internas suelen verse como una señal de confianza, la adición de 556 acciones representa menos del 0.2 % de la participación actual de Burdick y es insignificante para el flotante total de Centene. Por lo tanto, la transacción tiene un impacto fundamental limitado pero refuerza modestamente la alineación entre la dirección y los accionistas.

센틴 ì½”í¼ë ˆì´ì…� (CNC) â€� ë‚´ë¶€ìž� 거래 ì‹ ê³ ì„� Form 4

ì´ì‚¬ 케네스 A. 버딕ì¶Ä 2025ë…� 6ì›� 30ì�(거래 코드 A)ì—� 센틴 보통ì£� 556ì£�ë¥� 소규모로 장내 매수했다ê³� 보고했습니다. 주ì‹ì¶Ä $0.00ì� 명시ë� 가격으ë¡� ì·¨ë“ë˜ì—ˆìœ¼ë©°, ì´ëŠ” 현금 구매가 아닌 ë³´ìƒ ë˜ëŠ” 배당 재투ìžì™€ ê´€ë ¨ëœ ë°œí–‰ìž„ì„ ì‹œì‚¬í•©ë‹ˆë‹�. 거래 í›� 버딕ì� ì§ì ‘ 소유 지분ì¶� 367,052.924ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë˜í•œ 버딕 패밀ë¦� LLCë¥� 통해 보유í•� 86,498ì£� ê°„ì ‘ 소유 ì§€ë¶�ë� 보고하여 ì´� 경제ì � ì´ìµì¶Ä ì•� 453,600ì£�ì—� 달합니다.

신고섵ӗµç� 10,000ì£¼ì— ëŒ€í•� ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�ë� 공개ë˜ì–´ 있으ë©�, 행사가격ì¶� $80.57, 행사 ê°€ëŠ� 기간ì¶Ä 2025ë…� 2ì›� 7ì¼ë¶€í„� 2032ë…� 2ì›� 7ì¼ê¹Œì§€ìž…니ë‹�. 새로ìš� 파ìƒìƒí’ˆ 거래ëŠ� 기ë¡ë˜ì§€ 않았습니ë‹�.

ë‚´ë¶€ìž� 매수ëŠ� ì¼ë°˜ì ìœ¼ë¡� 신뢰 신호ë¡� 간주ë˜ì§€ë§�, 556ì£� 추가ëŠ� 버딕ì� 현재 ì§€ë¶„ì˜ 0.2% 미만ì´ë©° 센틴 ì „ì²´ 유통 주ì‹ìˆ˜ì— 중요하지 않ì¶� 수준입니ë‹�. ë”°ë¼ì„� ì� 거래ëŠ� 기본ì � ì˜í–¥ì¶Ä 제한ì �ì´ì§€ë§� ê²½ì˜ì§„ê³¼ 주주 ê°„ì˜ ì •ë ¬ì� 약간 강화합니ë‹�.

Centene Corporation (CNC) � Déclaration interne Formulaire 4

Le directeur Kenneth A. Burdick a déclaré une acquisition modeste de 556 actions ordinaires Centene sur le marché ouvert le 30 juin 2025 (code de transaction A). Les actions ont été acquises à un prix déclaré de 0,00 $, ce qui suggère que l’émission concerne une rémunération ou un réinvestissement de dividendes plutôt qu’un achat en espèces. Après la transaction, la détention directe de Burdick augmente à 367 052,924 actions. Il déclare également 86 498 actions indirectes détenues via Burdick Family LLC, portant son intérêt économique global à environ 453,6 mille actions.

La déclaration révèle également une option d’achat d’actions existante pour 10 000 actions avec un prix d’exercice de 80,57 $, exerçable à partir du 7 février 2025 et expirant le 7 février 2032. Aucune nouvelle transaction sur dérivés n’a été enregistrée.

Bien que les achats d’initiés soient généralement perçus comme un signe de confiance, l�ajout de 556 actions représente moins de 0,2 % de la participation actuelle de Burdick et est insignifiant par rapport au flottant total de Centene. La transaction a donc un impact fondamental limité, mais renforce modestement l’alignement entre la direction et les actionnaires.

Centene Corporation (CNC) � Form 4 Insider-Meldung

Direktor Kenneth A. Burdick meldete am 30. Juni 2025 einen geringfügigen Erwerb von 556 Centene-Stammaktien im offenen Markt (Transaktionscode A). Die Aktien wurden zu einem angegebenen Preis von $0,00 erworben, was darauf hindeutet, dass die Ausgabe im Zusammenhang mit Vergütung oder Dividendenreinvestition steht und kein Barkauf war. Nach der Transaktion erhöht sich Burdicks direkter Besitz auf 367.052,924 Aktien. Zudem berichtet er über 86.498 indirekte Aktien, die über Burdick Family LLC gehalten werden, womit sein gesamtes wirtschaftliches Interesse etwa 453,6 Tausend Aktien ²ú±ð³Ù°ùä²µ³Ù.

Die Meldung offenbart außerdem eine bestehende Aktienoption über 10.000 Aktien mit einem Ausübungspreis von $80,57, ausübbar ab dem 7. Februar 2025 und mit Ablauf am 7. Februar 2032. Neue Derivat-Transaktionen wurden nicht verzeichnet.

Obwohl Insider-Käufe üblicherweise als Vertrauenssignal gelten, stellt die Erhöhung um 556 Aktien weniger als 0,2 % von Burdicks aktuellem Bestand dar und ist für den Gesamtstreubesitz von Centene unbedeutend. Die Transaktion hat daher begrenzte fundamentale Auswirkungen, stärkt aber leicht die Ausrichtung zwischen Management und Aktionären.

Positive
  • None.
Negative
  • None.

Insights

TL;DR � Small insider buy; signals ongoing alignment but negligible financial impact.

Insider purchases usually indicate perceived undervaluation or commitment. Here, Burdick’s 556-share acquisition (~US$40-50k at recent prices) nudges his direct stake above 367k shares. Combined direct and indirect holdings equal ~453k shares, or roughly 0.08 % of Centene’s outstanding stock, so this filing is not material to float or control dynamics. No 10b5-1 plan is flagged, implying discretionary action. The unchanged 10,000-share option grant is routine disclosure. Overall, governance posture remains shareholder-friendly, but the event is too small to alter the investment thesis.

TL;DR � Neutral for valuation; insider buy size too minor to drive price.

From a portfolio perspective, a 556-share purchase in a US$46 bn market-cap company is noise. Burdick already held a sizeable position; incremental exposure does little to change his incentive structure. No earnings guidance or strategic update accompanies the filing, so cash-flow forecasts and multiples stand unchanged. I classify the event as not impactful for position sizing or risk budgeting.

Centene Corporation (CNC) � Comunicazione interna Form 4

Il direttore Kenneth A. Burdick ha segnalato un modesto acquisto sul mercato aperto di 556 azioni ordinarie Centene in data 30 giugno 2025 (codice transazione A). Le azioni sono state acquisite a un prezzo dichiarato di $0,00, suggerendo che l’operazione riguarda una compensazione o un reinvestimento di dividendi piuttosto che un acquisto in contanti. Dopo la transazione, la proprietà diretta di Burdick sale a 367.052,924 azioni. Riporta inoltre 86.498 azioni indirette detenute tramite Burdick Family LLC, portando il suo interesse economico aggregato a circa 453,6 mila azioni.

La comunicazione evidenzia anche un’opzione su azioni esistente per 10.000 azioni con un prezzo di esercizio di $80,57, esercitabile dal 7 febbraio 2025 e in scadenza il 7 febbraio 2032. Non sono state registrate nuove transazioni su strumenti derivati.

Pur essendo generalmente interpretati come un segnale di fiducia, i 556 azioni acquistate rappresentano meno dello 0,2% della partecipazione attuale di Burdick e sono irrilevanti rispetto al flottante complessivo di Centene. Pertanto, la transazione ha un impatto fondamentale limitato ma rafforza modestamente l’allineamento tra management e azionisti.

Centene Corporation (CNC) � Presentación interna Formulario 4

El director Kenneth A. Burdick reportó una modesta adquisición en el mercado abierto de 556 acciones ordinarias de Centene el 30 de junio de 2025 (código de transacción A). Las acciones fueron adquiridas a un precio declarado de $0.00, lo que sugiere que la emisión está relacionada con compensación o reinversión de dividendos en lugar de una compra en efectivo. Tras la transacción, la propiedad directa de Burdick aumenta a 367,052.924 acciones. También reporta 86,498 acciones indirectas mantenidas a través de Burdick Family LLC, sumando un interés económico agregado de aproximadamente 453.6 mil acciones.

La presentación también revela una opción sobre acciones existente para 10,000 acciones con un precio de ejercicio de $80.57, ejercitable desde el 7 de febrero de 2025 y con vencimiento el 7 de febrero de 2032. No se registraron nuevas transacciones de derivados.

Si bien las compras internas suelen verse como una señal de confianza, la adición de 556 acciones representa menos del 0.2 % de la participación actual de Burdick y es insignificante para el flotante total de Centene. Por lo tanto, la transacción tiene un impacto fundamental limitado pero refuerza modestamente la alineación entre la dirección y los accionistas.

센틴 ì½”í¼ë ˆì´ì…� (CNC) â€� ë‚´ë¶€ìž� 거래 ì‹ ê³ ì„� Form 4

ì´ì‚¬ 케네스 A. 버딕ì¶Ä 2025ë…� 6ì›� 30ì�(거래 코드 A)ì—� 센틴 보통ì£� 556ì£�ë¥� 소규모로 장내 매수했다ê³� 보고했습니다. 주ì‹ì¶Ä $0.00ì� 명시ë� 가격으ë¡� ì·¨ë“ë˜ì—ˆìœ¼ë©°, ì´ëŠ” 현금 구매가 아닌 ë³´ìƒ ë˜ëŠ” 배당 재투ìžì™€ ê´€ë ¨ëœ ë°œí–‰ìž„ì„ ì‹œì‚¬í•©ë‹ˆë‹�. 거래 í›� 버딕ì� ì§ì ‘ 소유 지분ì¶� 367,052.924ì£�ë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë˜í•œ 버딕 패밀ë¦� LLCë¥� 통해 보유í•� 86,498ì£� ê°„ì ‘ 소유 ì§€ë¶�ë� 보고하여 ì´� 경제ì � ì´ìµì¶Ä ì•� 453,600ì£�ì—� 달합니다.

신고섵ӗµç� 10,000ì£¼ì— ëŒ€í•� ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�ë� 공개ë˜ì–´ 있으ë©�, 행사가격ì¶� $80.57, 행사 ê°€ëŠ� 기간ì¶Ä 2025ë…� 2ì›� 7ì¼ë¶€í„� 2032ë…� 2ì›� 7ì¼ê¹Œì§€ìž…니ë‹�. 새로ìš� 파ìƒìƒí’ˆ 거래ëŠ� 기ë¡ë˜ì§€ 않았습니ë‹�.

ë‚´ë¶€ìž� 매수ëŠ� ì¼ë°˜ì ìœ¼ë¡� 신뢰 신호ë¡� 간주ë˜ì§€ë§�, 556ì£� 추가ëŠ� 버딕ì� 현재 ì§€ë¶„ì˜ 0.2% 미만ì´ë©° 센틴 ì „ì²´ 유통 주ì‹ìˆ˜ì— 중요하지 않ì¶� 수준입니ë‹�. ë”°ë¼ì„� ì� 거래ëŠ� 기본ì � ì˜í–¥ì¶Ä 제한ì �ì´ì§€ë§� ê²½ì˜ì§„ê³¼ 주주 ê°„ì˜ ì •ë ¬ì� 약간 강화합니ë‹�.

Centene Corporation (CNC) � Déclaration interne Formulaire 4

Le directeur Kenneth A. Burdick a déclaré une acquisition modeste de 556 actions ordinaires Centene sur le marché ouvert le 30 juin 2025 (code de transaction A). Les actions ont été acquises à un prix déclaré de 0,00 $, ce qui suggère que l’émission concerne une rémunération ou un réinvestissement de dividendes plutôt qu’un achat en espèces. Après la transaction, la détention directe de Burdick augmente à 367 052,924 actions. Il déclare également 86 498 actions indirectes détenues via Burdick Family LLC, portant son intérêt économique global à environ 453,6 mille actions.

La déclaration révèle également une option d’achat d’actions existante pour 10 000 actions avec un prix d’exercice de 80,57 $, exerçable à partir du 7 février 2025 et expirant le 7 février 2032. Aucune nouvelle transaction sur dérivés n’a été enregistrée.

Bien que les achats d’initiés soient généralement perçus comme un signe de confiance, l�ajout de 556 actions représente moins de 0,2 % de la participation actuelle de Burdick et est insignifiant par rapport au flottant total de Centene. La transaction a donc un impact fondamental limité, mais renforce modestement l’alignement entre la direction et les actionnaires.

Centene Corporation (CNC) � Form 4 Insider-Meldung

Direktor Kenneth A. Burdick meldete am 30. Juni 2025 einen geringfügigen Erwerb von 556 Centene-Stammaktien im offenen Markt (Transaktionscode A). Die Aktien wurden zu einem angegebenen Preis von $0,00 erworben, was darauf hindeutet, dass die Ausgabe im Zusammenhang mit Vergütung oder Dividendenreinvestition steht und kein Barkauf war. Nach der Transaktion erhöht sich Burdicks direkter Besitz auf 367.052,924 Aktien. Zudem berichtet er über 86.498 indirekte Aktien, die über Burdick Family LLC gehalten werden, womit sein gesamtes wirtschaftliches Interesse etwa 453,6 Tausend Aktien ²ú±ð³Ù°ùä²µ³Ù.

Die Meldung offenbart außerdem eine bestehende Aktienoption über 10.000 Aktien mit einem Ausübungspreis von $80,57, ausübbar ab dem 7. Februar 2025 und mit Ablauf am 7. Februar 2032. Neue Derivat-Transaktionen wurden nicht verzeichnet.

Obwohl Insider-Käufe üblicherweise als Vertrauenssignal gelten, stellt die Erhöhung um 556 Aktien weniger als 0,2 % von Burdicks aktuellem Bestand dar und ist für den Gesamtstreubesitz von Centene unbedeutend. Die Transaktion hat daher begrenzte fundamentale Auswirkungen, stärkt aber leicht die Ausrichtung zwischen Management und Aktionären.

0001831868false00018318682025-07-012025-07-010001831868us-gaap:CommonStockMember2025-07-012025-07-010001831868us-gaap:WarrantMember2025-07-012025-07-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 01, 2025

 

 

SeaStar Medical Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39927

85-3681132

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3513 Brighton Blvd,

Suite 410

 

Denver, Colorado

 

80216

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 844 427-8100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock par value $0.0001 per share

 

ICU

 

The Nasdaq Stock Market LLC

Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share

 

ICUCW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 7.01 Regulation FD Disclosure.

Press Release

On July 2, 2025, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing that the Company had received confirmation from the Nasdaq that the Company evidenced compliance with the $2.5 million Minimum Stockholders' Equity Requirement. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 8.01 Other Events

The Company has confirmed in a letter dated July 1, 2025, that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”). Nasdaq noted in its letter that to maintain compliance, the Company will have to raise additional funds, otherwise the Company will be below the Minimum Stockholders’ Equity Requirement by the end of July.

As previously disclosed by the Company in a Current Report on Form 8-K filed on March 11, 2025, the Company received a decision letter from the Nasdaq Hearings Panel (the “Panel”), granting the Company’s request to continue its listing on Nasdaq, subject to certain conditions. The Panel’s decision provided the Company with an exception until June 22, 2025, to demonstrate compliance with the Minimum Stockholders’ Equity Requirement for continued listing set forth in Nasdaq Listing Rule 5550(b).

Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until July 1, 2026. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Minimum Stockholders’ Equity Requirement, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company would not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff would not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor would the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff would issue a “Delist Determination Letter” and the Company would have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated July 2, 2025

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SeaStar Medical Holding Corporation

 

 

By:

/s/ Eric Schlorff

Date:

July 2, 2025

Name:

Eric Schlorff

 

 

Title:

Chief Executive Officer

 


FAQ

How many Centene (CNC) shares did Director Kenneth Burdick acquire on 30 June 2025?

He acquired 556 common shares.

What is Kenneth Burdick’s total direct share ownership after the transaction?

His direct holdings rose to 367,052.924 shares.

Does the director hold additional indirect Centene shares?

Yes, 86,498 shares are held indirectly through Burdick Family LLC.

What options does Kenneth Burdick hold in Centene?

He owns 10,000 stock options with a $80.57 strike, exercisable 7 Feb 2025 and expiring 7 Feb 2032.

Was this acquisition made under a Rule 10b5-1 trading plan?

The filing does not indicate that a Rule 10b5-1 plan was in effect.
SeaStar Medical Holding Corp

NASDAQ:ICU

ICU Rankings

ICU Latest News

ICU Latest SEC Filings

ICU Stock Data

6.83M
17.23M
2.09%
2.07%
4.1%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
DENVER